The National Health Service has introduced a new rapid diagnostic test for brain tumors that significantly reduces the time required to identify tumor type and initiate treatment. The test employs genomic sequencing technology to analyze the genetic code of tumor samples, delivering results in approximately two hours compared to the previous standard of up to eight weeks.
The technology uses a compact sequencing machine manufactured by Oxford Nanopore, combined with specialist software developed at the University of Nottingham in collaboration with hospital clinicians. During the diagnostic process, tissue samples are placed into the device, where DNA molecules pass through microscopic nanopores that reveal the tumor’s unique genomic profile. In some cases, results have been obtained within 20 minutes of the machine beginning operation.
One benefit of accelerated diagnosis involves surgical decision-making. Since some brain tumors are potentially curable and require aggressive surgical removal while others are too aggressive to safely remove completely, knowing the tumor type during surgery allows surgeons to adjust their approach in real time. Additionally, faster diagnosis enables patients to access clinical trials sooner and begin appropriate treatment without prolonged delays.
The NHS has launched a pilot program involving five specialist centers located in Nottingham, Birmingham, London, and Newcastle, with plans for later expansion to Bristol, Oxford, Leeds, and Manchester. According to NHS officials, no other health service is currently rolling out this technology across multiple hospital sites. More than 12,000 people in the UK are diagnosed annually with primary brain tumors, which represent the leading cancer killer among children and adults under 40.
Official statements characterize the initiative as a transformative development with potential to completely change how brain tumor diagnosis is conducted within the NHS. The pilot builds upon earlier work already underway in Nottingham and Birmingham, with the goal of establishing evidence supporting integration of rapid genomic testing into routine patient care across the country.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI